Oral PCSK9 Pill Cuts LDL Cholesterol by Up to 60% in Phase 3 Trial
A phase 3 trial of the daily oral PCSK9 inhibitor enlicitide showed LDL cholesterol falls by about 60% in 2,909 patients with atherosclerosis or high cardiovascular risk, many already on statins. The pill also reduced non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), with effects lasting one year. If FDA approves, enlicitide could offer an oral alternative to injectable PCSK9 therapies and improve adherence, though a separate study is needed to confirm whether these LDL reductions translate into fewer heart attacks and strokes. The trial was Merck-funded and ongoing work aims to determine cardiovascular event outcomes.
